MDxHealth (NASDAQ:MDXH) Issues Quarterly Earnings Results

MDxHealth (NASDAQ:MDXH) announced its earnings results on Thursday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01, Zacks reports. The business had revenue of $27.21 million for the quarter, compared to the consensus estimate of $26.14 million.

Here are the key takeaways from MDxHealth’s conference call:

• Q2 revenue rose 16% year over year to $27.2 million and 14% sequentially, while tissue-based testing volumes recovered by more than 1,400 tests following the ExoDx integration and sales-force restructuring.
• Management reaffirmed full-year revenue guidance of $110 million to $115 million and expects to return to adjusted EBITDA profitability as it exits 2026, citing continued growth and operating discipline.
• The company completed the wind-down of its Resolve UTI business and Plano laboratory, removing a $10.4 million contingent liability; it also raised $20 million in a registered direct offering, resulting in pro forma cash of approximately $39.2 million as of June 30.
• Gross margin declined to 65.7% from 68.6% a year earlier due to test mix, while the operating loss widened to $5.1 million and adjusted EBITDA was negative $2.3 million, primarily reflecting ExoDx-related operating expenses.
• Management highlighted potential growth from the peer-reviewed PROMPT study, the planned PROTECT study in active surveillance, and artificial intelligence initiatives supporting GPS, Confirm mdx, and ExoDx, while acknowledging that 2027 visibility remains preliminary.

MDxHealth Trading Up 74.9%

MDxHealth stock traded up $0.35 during midday trading on Friday, hitting $0.81. The stock had a trading volume of 322,955,163 shares, compared to its average volume of 2,545,347. MDxHealth has a 52-week low of $0.40 and a 52-week high of $5.33. The company has a market capitalization of $40.00 million, a PE ratio of -1.24 and a beta of 1.42. The firm’s fifty day moving average is $0.47 and its two-hundred day moving average is $1.79.

MDxHealth News Summary

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: MDxHealth reported second-quarter revenue of $27.2 million, up 16% year over year and above the approximately $26.1 million analyst estimate. The company’s $0.18 per-share loss was slightly better than the $0.19 consensus cited by MarketBeat, although another estimate tracked by Zacks showed a larger expected loss of $0.12. MDxHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed an optimistic FY 2026 revenue outlook of $110 million to $115 million, well above the roughly $98.8 million consensus estimate. This suggests management expects continued commercial momentum. MDxHealth Earnings Report
• Positive Sentiment: Management discussed the results and outlook during its second-quarter earnings call, giving investors additional detail on the company’s operating performance and growth plans. MDxHealth Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Trading in MDXH was temporarily paused several times under the exchange’s Limit Up-Limit Down mechanism. The halts do not represent a fundamental company announcement, but they underscore unusually high volatility and speculative trading activity.
• Negative Sentiment: MDxHealth agreed to raise $20 million through a direct share offering. The added funding may support operations and growth, but issuing new shares can dilute existing shareholders and may be contributing to the sharp price swings. MDxHealth Raises $20 Million in Direct Share Offering

Wall Street Analysts Forecast Growth

MDXH has been the subject of a number of analyst reports. Lake Street Capital set a $3.00 price objective on shares of MDxHealth and gave the company a “buy” rating in a research note on Friday. TD Cowen reiterated a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. BTIG Research cut their price target on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $2.83.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds have recently made changes to their positions in MDXH. Intesa Sanpaolo Wealth Management bought a new position in MDxHealth in the 4th quarter worth approximately $36,000. Lido Advisors LLC bought a new stake in shares of MDxHealth during the third quarter valued at approximately $48,000. Squarepoint Ops LLC purchased a new position in shares of MDxHealth in the fourth quarter worth $51,000. Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth in the third quarter worth $53,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of MDxHealth during the fourth quarter worth $68,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.